Candel Therapeutics Inc

General ticker "CADL" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $191.6M

Candel Therapeutics Inc follows the US Stock Market performance with the rate: 25.0%.

Estimated limits based on current volatility of 14.7%: low 7.11$, high 9.57$

Factors to consider:

  • Current price 286.7% above estimated high
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.69$, 2.23$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.01$, 2.93$]

Financial Metrics affecting the CADL estimates:

  • Negative: Non-GAAP EPS, $ of -1.30 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -53.75 <= 2.35
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term CADL quotes

Long-term CADL plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.12MM $0.12MM $0.00MM
Operating Expenses $25.85MM $34.85MM $38.39MM
Operating Income $-25.73MM $-34.72MM $-38.39MM
Non-Operating Income $-10.40MM $15.93MM $0.45MM
Interest Expense $0.05MM $0.49MM $0.51MM
R&D Expense $15.18MM $20.79MM $24.51MM
Income(Loss) $-36.12MM $-18.79MM $-37.94MM
Profit(Loss) $-36.12MM $-18.79MM $-37.94MM
Stockholders Equity $64.14MM $47.71MM $12.74MM
Assets $89.20MM $77.69MM $41.20MM
Operating Cash Flow $-22.22MM $-31.42MM $-34.24MM
Capital expenditure $1.83MM $1.30MM $0.46MM
Investing Cash Flow $-1.83MM $-1.30MM $-0.28MM
Financing Cash Flow $71.80MM $19.97MM $-0.12MM
Earnings Per Share* $-1.26 $-0.10 $-1.31

* EPS are Split Adjusted, recent splits may be reflected with a delay.